Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe

Healthy Volunteer Study Clinical Trial

Official title:

A Study to Assess the Effect of Food on the Bioavailability of Obicetrapib and Ezetimibe After Administration of a Fixed-Dose Combination Formulation of Obicetrapib/Ezetimibe, 10 mg/10 mg in Healthy Adult Subjects

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT06050291
• Other study ID #: OBEZ-103
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: January 20, 2024
• Est. completion date: April 2024

Study information

• Verified date: January 2024
• Source: NewAmsterdam Pharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will assess the effect of food on the bioavailability of obicetrapib and ezetimibe after a single-dose administration of a fixed-dose combination formulation of obicetrapib/ezetimibe, 10 mg/10 mg in healthy adult male and female subjects under fasted and fed conditions.

Description:

This is an open-label, single-dose, randomized, two-treatment, two-period, two-sequence crossover relative bioavailability study under fasted and fed conditions. It will assess the effect of food on the bioavailability of obicetrapib and ezetimibe after a single-dose administration of a fixed-dose combination formulation of obicetrapib/ezetimibe, 10 mg/10 mg in healthy adult male and female subjects under fasted and fed conditions. The screening period will be up to 28 days. Patients that are eligible will enter the clinical facility at least 10.5 hours prior to dosing. Depending on their randomization patients will be fed or fasted prior to dosing. They will remain confined for at least 24 hours. After leaving confinement, patients will return to the clinic 9 times for blood draws. At least 56 days after the first dosing, patients will return to the clinic and go through the same process. Those previously fed before dosing will be fasted and those previously fasted will be fed. Patients will return 9 times after their second confinement for additional blood draws.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 28
• Est. completion date: April 2024
• Est. primary completion date: April 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Key Inclusion Criteria:

• Males and Females aged 18 to 65.
• Body Mass Index (BMI) of 18.5-29.9 kg/m², inclusive.
• Females of childbearing potential must be willing to use approved method of birth control.
• Blood pressure 90/60 - 140/90 mmHg, inclusive.
• Hemoglobin level above lower limit of normal.
• Good health.

Key Exclusion Criteria:

• Females who are pregnant, lactating or likely to become pregnant during the study.
• History of allergy, sensitivity to obicetrapib, ezetimibe or any components of the study products, or history of any drug hypersensitivity or intolerance that may compromise the safety of the subject.
• Significant history or current evidence of chronic infectious disease, system disorders, organ dysfunction especially hypothyroidism, renal or hepatic disorders, cardiovascular disorders, respiratory disorders, diabetes or obesity.
• Clinically significant history or presence of gastrointestinal disease or history of malabsorption within the last year.
• History of psychiatric disorders occurring within the last two years that required the subject to be hospitalized or treated with medication.
• Presence of a medical condition requiring regular treatment with prescription drugs.
• Use of statins, cyclosporine, fibrates (e.g., fenofibrate), bile acid seuqstrants (e.g., cholestyramine), or coumarin anticoagulants within 30 days before initial dosing.
• Use of pharmacologic agents known to significantly induce or inhibit drug-metabolizing enzymes (especially inducers and inhibitors of CYP3A4) within 30 days before initial dosing.
• Use of any drug that can alter the absorption of other drugs by affecting gastrointestinal motility or by changing the gastric pH, in the opinion of the Investigator, within 14 days before initial dosing.
• Use of any drug that can increase or decrease the metabolism and excretion of the study drug, within 14 days before initial dosing.
• Receipt of any drug as part of a research study within 30 days before initial dosing.
• Previous participation in a research study with obicetrapib.
• Drug or alcohol addiction requiring treatment in the 12 months before initial dosing.
• History of excessive alcohol consumption (on average more than 14 units of alcohol/week) during the past 12 months.
• Donation or significant loss of whole blood (480 mL or more) within 30 days or plasma within 14 days before initial dosing.
• Positive test results for HIV, Hepatitis B surface antigen, or Hepatitis C antibody.
• Positive test results for drugs of abuse at screening.
• If female, has a positive pregnancy test at screening.
• Use of tobacco- or nicotine-containing products within 30 days before initial dosing.
• Difficulty swallowing tablets or capsules whole.

Related Conditions & MeSH terms

• Healthy Volunteer Study

Intervention

Drug:
• Fixed-Dose Combination (FDC) Tablet
Obicetrapib/Ezetimibe FDC tablet

Locations

Country	Name	City	State
United States	NOVUM	Las Vegas	Nevada

Sponsors (1)

Lead Sponsor	Collaborator
NewAmsterdam Pharma

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cmax	Maximum measured plasma concentration following each treatment.	528.00 hours
Primary	AUC0-t	Area under the plasma concentration versus time curve from time zero to the time of the last measurable plasma concentration, as calculated by linear trapezoidal method.	528.00 hours
Primary	AUC0-8	Area under the plasma concentration versus time curve from time zero to infinity where AUC0-8 = AUC0-t + Ct/?z. Ct is the last measurable concentration and ?z is the terminal rate constant.	528.00 hours
Secondary	Tmax	Time of the maximum measured plasma concentration. If the maximum value occurs at more than one time point, Tmax is defined as the first time point with this value.	528.00 hours
Secondary	Tlag	Time delay in achieving Tmax	528.00 hours
Secondary	?z	First order rate constant associated with the terminal (log-linear) portion of the curve.	528.00 hours
Secondary	t½	The terminal half-life will be calculated as ln(2)/?z.	528.00 hours
Secondary	CL/F	Apparent oral systemic clearance, calculated as Dose/AUC0-8	528.00 hours
Secondary	Vd/F	Apparent volume of distribution during terminal phase, calculated as Dose/(AUC0-8 × ?z)	528.00 hours
Secondary	R2 adjusted	Goodness of fit statistic for the terminal phase, adjusted for the number of points used in the estimation of ?z.	528.00 hours
Secondary	AUC_%Extrap_obs	The residual area in percentage will be determined by the formula, [(AUC0-8-AUC0-t)/AUC0-8] × 100.	528.00 hours